WO2014047476A1 - Compositions and methods for improving health in animals - Google Patents

Compositions and methods for improving health in animals Download PDF

Info

Publication number
WO2014047476A1
WO2014047476A1 PCT/US2013/060986 US2013060986W WO2014047476A1 WO 2014047476 A1 WO2014047476 A1 WO 2014047476A1 US 2013060986 W US2013060986 W US 2013060986W WO 2014047476 A1 WO2014047476 A1 WO 2014047476A1
Authority
WO
WIPO (PCT)
Prior art keywords
nutritional supplement
mmol
animal
amount
administering
Prior art date
Application number
PCT/US2013/060986
Other languages
French (fr)
Inventor
Amy L. HEATON
Mitchell K. FRIEDLANDER
Dennis W. GAY
Original Assignee
Quality Ip Holdings, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/623,111 external-priority patent/US8747923B2/en
Priority claimed from US13/623,113 external-priority patent/US8722115B2/en
Application filed by Quality Ip Holdings, Inc. filed Critical Quality Ip Holdings, Inc.
Priority to CA2885527A priority Critical patent/CA2885527C/en
Publication of WO2014047476A1 publication Critical patent/WO2014047476A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • Embodiments of the present disclosure generally relate to methods and nutritional supplements for improving health in animals.
  • animal means any species of the kingdom Animalia, including mammals, avians, reptiles or amphibians. It may include a food-producing animal (e.g., chicken, turkeys, ducks, geese, guinea henspig, cattle, lambs, fish, etc.); a pet, such as dog and cat; or a working animal, such as horse.
  • a food-producing animal e.g., chicken, turkeys, ducks, geese, guinea henspig, cattle, lambs, fish, etc.
  • a pet such as dog and cat
  • a working animal such as horse.
  • mammal means a warm blooded vertebrate, including non-human animals such as murine, porcine, canine and feline. It may include ungulates or hooved animals (e.g., cattle, goats, pigs, horse, sheep, etc.); rodents (e.g., guinea pigs, hamsters, mice, rats, etc.); lagomorphs such as rabbits; primates (e.g., monkeys, baboons, humans, etc.); or the like. By way of non-limiting examples, mammal may include cattle, sheep, goat, or swine.
  • rodents e.g., guinea pigs, hamsters, mice, rats, etc.
  • lagomorphs such as rabbits
  • primates e.g., monkeys, baboons, humans, etc.
  • mammal may include cattle, sheep, goat, or swine.
  • the cysteine may be n-acetyl L-cysteine, and the glutamine may be L-glutamine.
  • the amino acids may be delivered as non-toxic salts thereof, effective complexes thereof, stable chelates thereof, active esters thereof, functional derivatives thereof, or mixtures thereof, which are effective to increase growth hormone levels in animals.
  • the nutritional supplement may be present in an amount of 2.9 grams. Dosages are generally calculated in the range of about 20-50 gms per kg of body weight of the animal.
  • the nutritional supplement may be administered to animals orally.
  • the supplement may be in any acceptable and known oral formulation including, but are not limited to, powder, tablet, capsule, or liquid form.
  • a nutritional supplement for improving health of animals consisting essentially of L-lysine HC1, L-arginine HC1, oxo-proline, N-acetyl L-cysteine, L-glutamine, and schizonepeta (aerial parts) powder.
  • a functional dosage may include L-arginine HC1 at a level between 0.1-6 mmol, and oxo-proline at a level between 0.1-8 mmol, and/or the L-lysine HC1 in an amount between 0.1-12 mmol.
  • the n-acetyl L-cysteine and/or L-glutamine may be contained at a level between 0.001-6 mmol.
  • a functional dosage may include L-arginine HC1 at a level between 2.5-4.5 mmol, oxo-proline between 4-6 mmol, and/or the L-lysine HC1 in an amount between 7-9 mmol.
  • the n-acetyl L-cysteine and/or L-glutamine may be contained at a level between 0.001-0.5 mmol.
  • the nutritional supplement may be administered to animals orally.
  • the supplement may be in any acceptable and known oral formulation including, but are not limited to, powder, tablet, capsule, or liquid form.
  • the disclosed nutritional supplements may be administered to an animal to improve health, including by: increasing growth performance; enhancing lean body mass with an overall improvement in feed efficiency; improving reproductively performance; stimulating milk production; boosting milk yield; or combinations thereof.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Birds (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)

Abstract

A method of improving health in an animal includes administering to the animal a nutritional supplement comprising an amino acid secretagogue composition, which stimulates the pituitary gland in the animal to produce growth hormone. The nutritional supplement may be administered orally. The nutritional supplement may comprise L-arginine hydrochloride, L-pyroglutamic acid, L-lysine hydrochloride, and cysteine. When desired, the nutritional supplement may consist essentially of L-arginine hydrochloride, L-pyroglutamic acid, L-lysine hydrochloride, N-acetyl-L-cysteine, L-glutamine, and schizonepeta powder.

Description

COMPOSITIONS AND METHODS FOR IMPROVING HEALTH IN ANIMALS
PRIORITY CLAIM
This application claims the benefit of the filing date of United States Patent
Application Serial Number 13/623,113, filed September 20, 2012, for "COMPOSITIONS AND METHODS FOR IMPROVING HEALTH IN ANIMALS" and United States Patent Application Serial Number 13/623,111, filed September 20, 2012, for "COMPOSITIONS AND METHODS FOR IMPROVING HEALTH IN CANINES."
TECHNICAL FIELD
Embodiments of the present disclosure generally relate to methods and nutritional supplements for improving health in animals.
BACKGROUND
Growth hormone is an anabolic hormone capable of promoting linear growth, weight gain and whole body nitrogen retention in animals. Growth hormone is produced in somatotroph cells of the anterior pituitary gland of animals and secreted throughout life. It is mainly controlled in the brain by two hypothalamic peptides: growth hormone releasing hormone (GHRH), which stimulates its secretion and synthesis; and somatostatin, which inhibits them. Growth hormone is known to promote skeletal growth, to increase nitrogen retention and protein synthesis, and to affect glucose and lipid metabolism in animals.
As animal grows older, the growth hormone undergoes considerable decrement resulting in a loss of skeletal muscle mass, osteoporosis, increased fat deposition and decreased lean body mass. It has been demonstrated that the development of these changes can be offset by recombinant growth hormone therapy. However, current recombinant growth hormone therapy has several shortcomings, including frequent subcutaneous or intravenous injections, insulin resistance and impaired glucose tolerance.
Growth hormone has been administered to animals to offset the growth hormone deficiency in aged animals. Furthermore, there are reports of using growth hormone to boost certain desirable performances of animals. For example, growth hormone has been used to enhance growth performance in animals by increasing lean body mass with an overall improvement in feed efficiency, and to enhance fertility in animals. Additionally, growth hormone has been used to stimulate milk production and achieve an enhanced milk yield in mammals.
U.S. Patent 4,521,409, issued on June 4, 1985 to Bauman, and U.S. Patent 5,004,728, issued on April 2, 1991 to Chalupa disclose the administration of growth hormone to cattle and ruminants to stimulate milk production with an increase in feed to milk conversion. In U.S. Patent 5,416,073, issued on May 16, 1995 to Coy, growth hormone is used to increase milk production in dairy cows and to increase growth rates in animals such as cattle, sheep, and swine.
U.S. Patent 5,008,244, issued on April 16, 1991 to Miller discloses an administration of growth hormone to food-producing animals to increase their fertility by improving embryonic survival and litter size during the reproductive stage of growth. In U.S. Patent 5,583,106, issued on December 10, 1996 to Stanisiewski, an enhanced reproductive performance in cattle is achieved by commencing administration of growth hormone during the early postpartum period.
U.S. Patent 5,637,566, issued on June 10, 1997 to Walker et al. describes the use of growth hormone to improve carcass quality and/or food conversion efficiency in animals. In U.S. Patent 4,792,546, issued on December 20, 1988 to Baker, growth hormone is administered to food-producing animals to increase weight gain and at the same time reduce fat deposition and improve the lean meat to fat ratio.
U.S. Patent 7,361,642, issued on April 22, 2008 to Draghia-Akli, discloses a method for increasing growth hormone in canines. A canine-specific growth hormone releasing hormone (dGHRH) or a nucleic acid molecule that encodes the dGHRH is administered to canines to increase the level of growth hormone secretion. The canines treated with specific growth hormone releasing hormone show increased insulin-like growth factor I, enhanced red blood cells production and hemoglobin concentration, and improved protein metabolism.
Journal of Orthopedic Research 15:519-527 (1997) discloses that a growth hormone secretagogue, MK-0677, elevates levels of serum insulin-like growth factor-I in canines, which in turn increases the size and strength of the quadriceps muscle in canines during remobilization.
U.S. Publication No. 2008/0119819, published on May 22, 2008 to Hojby, discloses that an administration of growth hormone enhances bone growth factors and fracture healing in canines.
It has also been reported that for adult canines of both sexes, exogenous growth hormone induces a marked increase in new bone formation. (Calcified Tissue Research 10(1): 1-13 (1972)).
Other studies have shown that in the canines that were given growth hormone, the quantity of protein in the blood plasma is increased, and the plasma protein pattern is altered. (Endocrinology 53: 134-162 (1953)). Additionally, it is known that growth hormone treatment improves protein metabolism in canines.
DISCLOSURE
The present disclosure includes a nutritional supplement and a method of using the same for improving health in animals, such as canines. The nutritional supplement is an amino acid secretagogue composition, which stimulates the pituitary gland of animals to release growth hormone.
A particular embodiment of the present disclosure relates to a nutritional supplement for improving health in animals, the nutritional supplement comprising L-arginine, L-pyroglutamic acid, L-lysine, and cysteine.
Another particular embodiment relates to a nutritional supplement for improving health in animals, the nutritional supplement consisting essentially of L-arginine hydrochloride, L-pyroglutamic acid, L-lysine hydrochloride, N-acetyl-L-cysteine, L-glutamine and schizonepeta powder.
Other embodiments are drawn to methods of increasing growth hormone in animals, the methods including administering the disclosed nutritional supplement to an animal. In particular embodiments, the method includes orally administering the disclosed nutritional supplement to an animal.
MODE(S) FOR CARRYING OUT THE INVENTION The present disclosure relates to methods and nutritional supplements for improving health in animals. The nutritional supplement is an amino acid secretagogue composition, which stimulates the pituitary gland in an animal to produce growth hormone. Increased production of growth hormone in animals may prevent the loss of skeletal muscle mass, osteoporosis, increased fat deposition, decreased lean body mass, and other disorders. The supplement of the present disclosure may work as a dietary supplement by assisting the animal's ability to secrete growth hormone naturally in a manner which is safe and effective.
As used herein, the term "animal" means any species of the kingdom Animalia, including mammals, avians, reptiles or amphibians. It may include a food-producing animal (e.g., chicken, turkeys, ducks, geese, guinea henspig, cattle, lambs, fish, etc.); a pet, such as dog and cat; or a working animal, such as horse.
As used herein, the term "mammal" means a warm blooded vertebrate, including non-human animals such as murine, porcine, canine and feline. It may include ungulates or hooved animals (e.g., cattle, goats, pigs, horse, sheep, etc.); rodents (e.g., guinea pigs, hamsters, mice, rats, etc.); lagomorphs such as rabbits; primates (e.g., monkeys, baboons, humans, etc.); or the like. By way of non-limiting examples, mammal may include cattle, sheep, goat, or swine.
A particular embodiment of the present disclosure relates to a nutritional supplement for improving health of animals, the nutritional supplement including L-lysine, L-arginine, oxo-proline, and at least one of cysteine and glutamine. The supplement may additionally include both cysteine and glutamine and/or schizonepeta powder. In particular embodiments, a functional dosage may include L-arginine at a level between 0.1-6 mmol, oxo-proline at a level between 0.1-8 mmol, and/or the L-lysine in an amount between 0.1-12 mmol. The cysteine and/or glutamine may be contained at a level between 0.001-6 mmol. The cysteine may be n-acetyl L-cysteine, and the glutamine may be L-glutamine. The amino acids may be delivered as non-toxic salts thereof, effective complexes thereof, stable chelates thereof, active esters thereof, functional derivatives thereof, or mixtures thereof, which are effective to increase growth hormone levels in animals. The nutritional supplement may be present in an amount of 2.9 grams. Dosages are generally calculated in the range of about 20-50 gms per kg of body weight of the animal. The nutritional supplement may be administered to animals orally. The supplement may be in any acceptable and known oral formulation including, but are not limited to, powder, tablet, capsule, or liquid form.
Another particular embodiment relates to a nutritional supplement for improving health of animals, the nutritional supplement consisting essentially of L-lysine HC1, L-arginine HC1, oxo-proline, N-acetyl L-cysteine, L-glutamine, and schizonepeta (aerial parts) powder. In particular embodiments, a functional dosage may include L-arginine HC1 at a level between 0.1-6 mmol, and oxo-proline at a level between 0.1-8 mmol, and/or the L-lysine HC1 in an amount between 0.1-12 mmol. The n-acetyl L-cysteine and/or L-glutamine may be contained at a level between 0.001-6 mmol. In another particular embodiment, a functional dosage may include L-arginine HC1 at a level between 2.5-4.5 mmol, oxo-proline between 4-6 mmol, and/or the L-lysine HC1 in an amount between 7-9 mmol. The n-acetyl L-cysteine and/or L-glutamine may be contained at a level between 0.001-0.5 mmol. The nutritional supplement may be administered to animals orally. The supplement may be in any acceptable and known oral formulation including, but are not limited to, powder, tablet, capsule, or liquid form.
Other embodiments are drawn to methods of increasing growth hormone in animals, the methods including administering the disclosed nutritional supplement to an animal. In particular embodiments, the method includes orally administering the disclosed nutritional supplement to an animal. The amount of dosage and frequency of administration may be varied according to many factors including, but are not limited to, animal species, ages and health.
The disclosed nutritional supplements may be administered to an animal to improve health, including by: increasing growth performance; enhancing lean body mass with an overall improvement in feed efficiency; improving reproductively performance; stimulating milk production; boosting milk yield; or combinations thereof.
In accordance with the "consist essentially of and "consisting essentially of language, the nutritional supplement is essentially limited to the aforementioned ingredients and does not include any additional active ingredients intended to add nutritional content (e.g., vitamins, minerals, etc.), but may include additional ingredients not intended to add nutritional content such as ingredients intended to fulfill a non-nutritional purpose (e.g., coloring, fillers, flavoring, an ingredient for maintaining the structural form, etc.).
Each ingredient of the nutritional supplement may be prepared in accordance with any method known to one of ordinary skill in the art. Alternatively, each ingredient may be obtained in a fully prepared from a commercially available source.
The nutritional supplement may be in any suitable oral administration form, including but not limited to: a chewable form, a liquid form, a spray form, a capsule form, a suppository form, dissolvable wafer, and a powder form.
Irrespective of the structural form of the nutritional supplement, the ingredients of the nutritional supplement may be distributed homogeneously or non-homogeneously within the nutritional supplement.
The nutritional supplement may be administered to an animal on a regular basis, such as a weekly or monthly intake at a dosage tailored to the animal's needs; i.e., the nutritional supplement may be administered regularly as multiples (1 χ, 2x, etc.) of the structural units (pills, tablets, capsules, etc.) in accordance with the needs of the animal. For example, an elderly animal is likely to need higher daily doses than does a young animal. Alternatively, the nutritional supplement may be administered on an as-needed basis at a dosage tailored to the animal's needs, such as administering the nutritional supplement to cattle during the early postpartum period to enhance reproductively performance. Veterinarian counseling may be beneficial for arriving at a desirable or optimal dosage tailored to the animal's needs.
The combination of types of amino acids, mass ranges, and specific formulations may be selected to be synergistically balanced and of adequate quantity to achieve the desired physiological effect, namely, growth hormone release. Improper combinations of the amino acids may be ineffective. The component amino acids are synergistic in the sense that several of them when combined together, synergistically stimulate the release of human growth hormone. The combination may also be chosen to reduce or inhibit chemical combination or reaction between the amino acids.
EXAMPLES
Example 1 The short-term effects of the disclosed supplement on the growth hormone level in animals are tested two hours after administration. The animal subjects are administered the capsules of supplement (SE OVITAL®) or an identical looking placebo. SEROVITAL® is a blend of 1-lysine HC1, 1-arginine HCL, oxo-proline, N-acetyl-l-cysteine, 1-glutamine, and schizonepeta (aerial parts) powder. Animal subjects are administered approximately 35 gms per kg of body weight. Blood is drawn at 15, 30, 60 and 90 and 120 minutes for assay. The growth hormone level is measured at each time point using the Siemens Immulite 2000 (intra-assay CV was 3.72%, inter-assay CV was 5.70%, and the detection limit for GH was 0.05ng/ml). The 15 and 120 minute time points are additionally assayed for triiodothyronine (T3) as informative for mechanistic investigations.
The mean growth hormone in the animal subjects are increased more than 600% after the administration of supplement from 0.17 at baseline to 1.33ng/ml at 120 minutes, while there is are no increases observed in the mean growth hormone of the animal subjects after the administration of placebo.
The growth hormone levels from baseline to 120 minutes (the growth hormone level at 120 minutes minus the growth hormone level at 0 minute), are increased about two fold when compared to the administration of a placebo. Overall, 120 minutes after the administration of the supplement, the growth hormone levels are significantly higher in absolute levels or by AUC.
Furthermore, the animals that were administered SEROVITAL® will exhibit a deceased reduction inT3 by nearly one-half over the same time period, compared to the animals administered with the placebo. These results affirm that somatostatin inhibition plays a mechanistic role in the ability of SEROVITAL® to induce significant increases in serum growth hormone levels in animal subjects.
These findings demonstrate that a specialized low-dose amino acid supplement can significantly increase short-term growth hormone levels in animals.
Example 2
The effect of the nutritional supplement on endurance and fat metabolism in animals are investigated. Each animal subject is measured for baseline weight, height, body fat percent and resting metabolic rate. Then, each animal subject is administered with the supplement SE O VITAL®, which is a blend of 1-lysine HC1, 1-arginine HC1, oxo-proline, N-acetyl-l-cysteine, 1-glutamine, and schizonepeta (aerial parts) powder for 2 weeks before being measured again for weight, height, body fat percent and resting metabolic rate. The measurements before and after the administration of the supplement are analyzed.
Mean V02max of the animal subjects increases compared to baseline. After the period of supplementation with SERO VITAL®, the mean RMR increases compared to baseline (P=0.165). Estimated daily calorie expenditure also increases.
After two weeks of supplementation with the supplement SERO VITAL®, both RMR and estimated daily calorie expenditure of the animal subjects tend to increase, evidencing the potential of the supplement to impart long-term fat burning effects. Additionally, endurance as measured by V02max in the post-absorptive state significantly improves. Overall, the animal subjects administered with the SERO VITAL® supplement will show enhanced parameters of endurance, energy, and vitality.
Example 3
The effect of the nutritional supplement on lean body mass and weight change of animals is studied. The animal subjects in the first group are given daily doses of the nutritional supplement for 6 months at different dosing concentrations of active ingredients, while the animal subjects in the second group are given placebo. Weight, percent lean body mass, and percent fat body mass are chosen as primary measures of body composition at the 6 month analysis period. The weight, body composition, and physical performance (including endurance) of the animal subjects are determined before and after the treatment, along with hormonal data analysis.
The animal subjects treated with the nutritional supplement show a sustained increase in lean body mass and an improved physical performance.
While embodiments of the present invention have been described herein for purposes of illustration, many modifications and changes will become apparent to those skilled in the art. Accordingly, the appended claims are intended to encompass all such modifications and changes as fall within the true spirit and scope of this invention.

Claims

What is claimed is: 1. A method of improving health in an animal, comprising:
providing a nutritional supplement, comprising:
L-arginine;
oxo-proline; and
L-lysine; and
administering the nutritional supplement to the animal.
2. The method of claim 1, wherein the nutritional supplement comprises the L-arginine in an amount from 0.1 to 6 mmol and the oxo-proline in an amount from 0.1 to 8 mmol.
3. The method of claim 1, wherein the nutritional supplement comprises the L-lysine in an amount from 0.1 to 12 mmol.
4. The method of claim 1, wherein the nutritional supplement comprises the L-arginine in an amount from 2.5 to 4.5 mmol, and the oxo-proline in an amount from 4 to 6 mmol.
5. The method of claim 1, wherein the nutritional supplement comprises the L-lysine in an amount from 7 to 9 mmol.
6. The method of claim 1, wherein administering the nutritional supplement comprises orally administering.
7. The method of claim 1, wherein administering the nutritional supplement comprises administering about 20-50 gms/kg of the nutritional supplement.
8. The method of claim 1, wherein the nutritional supplement is in powder, tablet, capsule, liquid, or wafer form.
9. The method of claim 1, wherein the nutritional supplement is administered once a week or once a month.
10. The method of claim 1, wherein the nutritional supplement is administered for at least one of following in the animal: increasing growth performance, enhancing lean body mass, improving reproductively performance, stimulating milk production, boosting milk yield, and increasing a feed efficiency.
11. The method of claim 1 , wherein the animal is a canine.
12. A method of improving health in an animal, comprising:
providing a nutritional supplement, comprising:
L-arginine hydrochloride in an amount from 0.1 to 6 mmol;
oxo-proline in an amount from 0.1 to 8 mmol;
L-lysine hydrochloride in an amount from 0.1 to 12 mmol; and
at least one of n-acetyl L-cysteine and L-glutamine; and
administering the nutritional supplement to the animal.
13. The method of claim 12, wherein the nutritional supplement comprises the L-arginine hydrochloride in an amount from 2.5 to 4.5 mmol, the oxo-proline in an amount from 4 to 6 mmol, and the L-lysine hydrochloride in an amount from 7 to 9 mmol.
14. The method of claim 12, wherein the nutritional supplement comprises n-acetyl L-cysteine and/or L-glutamine in an amount from 0.001 to 0.5 mmol.
15. The method of claim 12, wherein administering the nutritional supplement comprises orally administering the nutritional supplement.
16. The method of claim 12, wherein administering the nutritional supplement comprises administering about 20-50 gms/kg of the nutritional supplement.
17. The method of claim 12, wherein the nutritional supplement is in powder, tablet, capsule, liquid, or wafer form.
18. The method of claim 12, wherein the nutritional supplement is administered once a week or once a month.
19. The method of claim 12, wherein the nutritional supplement further comprises L-glutamine.
20. The method of claim 12, wherein the nutritional supplement further comprises schizonepeta powder.
21. The method of claim 12, wherein the nutritional supplement is administered for at least one of following in the animal: increasing growth performance, enhancing lean body mass, improving reproductively performance, stimulating milk production, boosting milk yield, and increasing a feed efficiency.
22. 11. The method of claim 12, wherein the animal is a canine.
PCT/US2013/060986 2012-09-20 2013-09-20 Compositions and methods for improving health in animals WO2014047476A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2885527A CA2885527C (en) 2012-09-20 2013-09-20 Compositions and methods for improving health in animals

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13/623,113 2012-09-20
US13/623,111 2012-09-20
US13/623,111 US8747923B2 (en) 2012-09-20 2012-09-20 Methods for improving health in canines
US13/623,113 US8722115B2 (en) 2012-09-20 2012-09-20 Methods for improving health in animals

Publications (1)

Publication Number Publication Date
WO2014047476A1 true WO2014047476A1 (en) 2014-03-27

Family

ID=50341977

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/060986 WO2014047476A1 (en) 2012-09-20 2013-09-20 Compositions and methods for improving health in animals

Country Status (2)

Country Link
CA (1) CA2885527C (en)
WO (1) WO2014047476A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122234A1 (en) * 1998-08-18 2004-06-24 Hauser Kenneth Lee Growth Hormone secretagogues
US20080050777A1 (en) * 2004-12-22 2008-02-28 Ambrx, Inc. Methods for Expression and Purification of Recombinant Human Growth Hormone
US20100186121A1 (en) * 2008-08-29 2010-07-22 Los Alamos National Security, Llc Transgenic Plants with Enhanced Growth Characteristics

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122234A1 (en) * 1998-08-18 2004-06-24 Hauser Kenneth Lee Growth Hormone secretagogues
US20080050777A1 (en) * 2004-12-22 2008-02-28 Ambrx, Inc. Methods for Expression and Purification of Recombinant Human Growth Hormone
US20100186121A1 (en) * 2008-08-29 2010-07-22 Los Alamos National Security, Llc Transgenic Plants with Enhanced Growth Characteristics

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHROMIAK, J. A. ET AL.: "Use of amino acids as growth hormone-releasing agents by athletes", NUTRITION, vol. 18, 2002, pages 657 - 661 *
COLLIER, S. R. ET AL.: "Growth hormone responses to varying doses of oral arginine", GROWTH HORMONE & IGF RESEARCH, vol. 15, 2005, pages 136 - 139 *

Also Published As

Publication number Publication date
CA2885527A1 (en) 2014-03-27
CA2885527C (en) 2021-07-20

Similar Documents

Publication Publication Date Title
US8722115B2 (en) Methods for improving health in animals
US9238024B2 (en) Methods for improving health in canines
JP6796097B2 (en) Composition and usage of anorexia control compound
US20140080888A1 (en) Methods for increasing endurance and fat metabolism in humans
US20220241259A1 (en) Compositions and methods using trigonelline and vitamins for preventing or treating conditions or disorders in skeletal muscle
KR20100094485A (en) Anti-fatigue agent comprising amino acid composition
TW201417809A (en) Methods for increasing human growth hormone levels
TW201424728A (en) Compositions and methods for increasing human growth hormone levels
JPH0923825A (en) Nutrition composition for horse
EP4331601A1 (en) Food composition and pharmaceutical composition for preventing or alleviating sarcopenia, containing low-molecular-weight collagen as active ingredient
CA2885527C (en) Compositions and methods for improving health in animals
JPWO2007077995A1 (en) Muscle bulking agent
US20220241266A1 (en) Compositions and methods using trigonelline and high protein for preventing or treating conditions or disorders in skeletal muscle
JP6677775B2 (en) Muscle builders
US20220265625A1 (en) Compositions and methods using trigonelline and minerals for preventing or treating conditions or disorders in skeletal muscle
JP2008546834A (en) Parenteral selenomethionine for the production of selenium rich foods
WO2020243975A1 (en) Use of nutraceutical composition in animal feed
CA2885566A1 (en) Compositions and methods for increasing human growth hormone levels

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13838314

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2885527

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13838314

Country of ref document: EP

Kind code of ref document: A1